help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First Published Online April 2, 2009
The Oncologist, Vol. 14, No. 4, 391-398, April 2009; doi:10.1634/theoncologist.2008-0240
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2008-0240v1
14/4/391    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harzstark, A. L.
Right arrow Articles by Small, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harzstark, A. L.
Right arrow Articles by Small, E. J.

Genitourinary Cancer

Immunotherapeutics in Development for Prostate Cancer

Andrea L. Harzstark, Eric J. Small

Department of Medicine, University of California – San Francisco, San Francisco, California, USA

Key Words. Castration-resistant prostate cancer • GM-CSF • Immunotherapy • Phase II • PROSTVACTM • GVAX® • Ipilimumab • Sipuleucel-T

Correspondence: Andrea L. Harzstark, M.D., Department of Medicine, University of California – San Francisco, 1600 Divisadero Street, Box 1711, San Francisco, California 94115, USA. Telephone: 415-353-7095; Fax: 415-353-7779; e-mail: Andrea.harzstark{at}ucsf.edu

Received November 5, 2008; accepted for publication February 28, 2009; first published online in THE ONCOLOGIST Express on April 2, 2009.

Disclosures: Andrea L. Harzstark: None; Eric J. Small: None.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers.

Whereas chemotherapy is the standard of care for metastatic castration-resistant prostate cancer and is associated with a survival benefit, there remains a need for alternative approaches. Extensive work has been done evaluating multiple immunotherapies for the treatment of prostate cancer. This review discusses clinical results for the most promising developments. These include cytokine-based therapy with GM-CSF; vaccines; antibody-based immunotherapies, including anti–cytotoxic T lymphocyte associated antigen 4 therapy and antibodies against additional targets; and dendritic cell-based immunotherapy.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.